Investigational new drugs
-
Investigational new drugs · Feb 2012
Comparative StudyPredictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.
This study aimed to define predictive factors of pathologic complete response (pCR) and disease progression in stage II and III breast cancer patients. ⋯ Patients with ER-/PR-/HER2+ tumors and those who received taxane-containing regimen achieved a higher pCR rate, while significantly more patients developed tumor progression by preoperative non-taxane-containing regimen (AC) compared to those who received taxane-containing chemotherapy.